serine and Neoplasms studies

Serine: A non-essential amino acid occurring in natural form as the L-isomer. It is synthesized from GLYCINE or THREONINE. It is involved in the biosynthesis of PURINES; PYRIMIDINES; and other amino acids.
serine : An alpha-amino acid that is alanine substituted at position 3 by a hydroxy group.

Neoplasms: New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.

Research Excerpts

Excerpt	Relevance	Reference
" The study investigated the expression of p53 protein phosphorylated at serine 20 (Ser20) and Ser392 and the association between clinicopathological parameters of ovarian neoplasms with respect to p53 protein overexpression."	7.75	Expression of p53 protein phosphorylated at serine 20 and serine 392 in malignant and benign ovarian neoplasms: correlation with clinicopathological parameters of tumors. ( Bar, JK; Gryboś, M; Noga, L; Rabczyńki, J; Słomska, I, 2009)
"While PHGDH is often overexpressed in cancer cells, how it is regulated has been unclear."	5.56	Parkin on serine: a Parkinson disease gene suppresses serine synthesis in cancer. ( Dalton, WB, 2020)
"Here we show that human cancer cells rapidly use exogenous serine and that serine deprivation triggered activation of the serine synthesis pathway and rapidly suppressed aerobic glycolysis, resulting in an increased flux to the tricarboxylic acid cycle."	5.39	Serine starvation induces stress and p53-dependent metabolic remodelling in cancer cells. ( Berkers, CR; Blyth, K; Gottlieb, E; Maddocks, OD; Mason, SM; Vousden, KH; Zheng, L, 2013)
"In this review, we summarize layers of evidence demonstrating that disordered metabolisms in glucose, glutamine, lipid, and serine caused by LKB1 deficiency promote carcinogenesis and non-neoplastic diseases."	5.12	LKB1 deficiency-induced metabolic reprogramming in tumorigenesis and non-neoplastic diseases. ( Meng, Q; Sun, Q; Wang, Y; Xu, ZX; Zhang, Y; Zhou, H, 2021)
"5-Fluorouracil (5-FU) is a key component of chemotherapy for colorectal cancer (CRC)."	4.12	SHMT2-mediated mitochondrial serine metabolism drives 5-FU resistance by fueling nucleotide biosynthesis. ( Arcangeli, A; Caselli, A; Chiarugi, P; Cirri, P; Colantuoni, V; Leo, A; Lottini, T; Maddocks, ODK; Muccillo, L; Nesi, I; Paoli, P; Pardella, E; Parri, M; Pranzini, E; Raugei, G; Sabatino, L; Santi, A; Taddei, ML; Uribe, AH; Zhang, T, 2022)
" The study investigated the expression of p53 protein phosphorylated at serine 20 (Ser20) and Ser392 and the association between clinicopathological parameters of ovarian neoplasms with respect to p53 protein overexpression."	3.75	Expression of p53 protein phosphorylated at serine 20 and serine 392 in malignant and benign ovarian neoplasms: correlation with clinicopathological parameters of tumors. ( Bar, JK; Gryboś, M; Noga, L; Rabczyńki, J; Słomska, I, 2009)
"Cancer is defined by unrestrained cell proliferation due to impaired protein activity."	3.01	The NEK family of serine/threonine kinases as a biomarker for cancer. ( Evan Prince, S; Panchal, NK, 2023)
"The vital role of serine metabolism in oncogenesis, tumor stemness, tumor immunity, and therapeutic resistance is outlined."	3.01	Serine Metabolic Reprogramming in Tumorigenesis, Tumor Immunity, and Clinical Treatment. ( Guanbin, S; Junyu, J; Li, Y; Shunxi, W; Wanqian, L; Xiaoxue, Y, 2023)
"MARK4 is associated with various cancer types due to its important role in regulating microtubule dynamics and subsequent cell division."	2.82	Microtubule-affinity regulating kinase 4: A potential drug target for cancer therapy. ( Anwar, S; Hasan, GM; Hassan, MI; Islam, A; Shahwan, M, 2022)
"Conventional therapies for malignant tumors have limitations and disadvantages."	2.82	Current status of cancer starvation therapy. ( Li, J; Lin, J; Tong, D, 2022)
"SERPINA3 seems to have cancer- and compartment-specific biological functions, acting either as a tumour promoter or suppressor in different cancers."	2.82	Unfolding the cascade of SERPINA3: Inflammation to cancer. ( Asha Nair, S; Soman, A, 2022)
"Since early detection of cancer is critical, this review discusses the potential of MLK3 as a predictive biomarker, which could likely help in clinical decision-making."	2.82	The role of mixed lineage kinase 3 (MLK3) in cancers. ( Ramachandraiah, K; Thylur Puttalingaiah, R, 2022)
" Pharmacokinetic analyses did not show any relevant drug interactions."	2.79	A phase I pharmacokinetic study of the vascular disrupting agent ombrabulin (AVE8062) and docetaxel in advanced solid tumours. ( Dieras, V; Eskens, FA; Fontaine, H; Hospitel, M; Oprea, C; Tosi, D; Tresca, P; Van der Gaast, A; Van Doorn, L; Veyrat-Follet, C, 2014)
" Ombrabulin clearance was high with a short terminal half-life and a medium volume of distribution."	2.79	Phase I clinical and pharmacokinetic study of ombrabulin (AVE8062) combined with cisplatin/docetaxel or carboplatin/paclitaxel in patients with advanced solid tumors. ( Bahleda, R; Capri, G; Daglish, B; Del Conte, G; Gianni, L; Hospitel, M; Oprea, C; Sessa, C; Soria, JC; Varga, A, 2014)
" Pharmacokinetic parameters were comparable to those in non-Japanese patients."	2.79	An open-label, dose-escalation, safety, and pharmacokinetics phase I study of ombrabulin, a vascular disrupting agent, administered as a 30-min intravenous infusion every 3 weeks in Japanese patients with advanced solid tumors. ( Fujisaka, Y; Hayashi, H; Kiyota, H; Kurata, T; Kuroda, S; Murakami, H; Nakagawa, K; Ono, A; Onozawa, Y; Takahashi, T; Tanaka, K; Watanabe, J; Yamamoto, N, 2014)
" Safety, tumor response, pharmacokinetics, and pharmacodynamic biomarkers were evaluated."	2.78	Phase I safety, pharmacokinetic and pharmacodynamic evaluation of the vascular disrupting agent ombrabulin (AVE8062) in patients with advanced solid tumors. ( Bahleda, R; Braghetti, A; Cohen, P; Delmonte, A; Farace, F; Hospitel, M; Lassau, N; Lorusso, P; Sessa, C; Soria, JC; Tolcher, A; Veyrat-Follet, C, 2013)
"Here, we review its role in cancer by focusing on key enzymes with tumor-promoting functions and important products of the SGOCP that are of physiological relevance for tumorigenesis."	2.66	The complexity of the serine glycine one-carbon pathway in cancer. ( Diaz-Meco, MT; Moscat, J; Reina-Campos, M, 2020)
"Serine encounters diverse fates in cancer cells, including being charged onto tRNAs for protein synthesis, providing head groups for sphingolipid and phospholipid synthesis, and serving as a precursor for cellular glycine and one-carbon units, which are necessary for nucleotide synthesis and methionine cycle reloading."	2.66	Reprogramming of serine, glycine and one-carbon metabolism in cancer. ( Li, AM; Ye, J, 2020)
"While metabolic reprogramming of cancer cells has long been considered from the standpoint of how and why cancer cells preferentially utilize glucose via aerobic glycolysis, the so-called Warburg Effect, the progress in the following areas during the past several years has substantially advanced our understanding of the rewired metabolic network in cancer cells that is intertwined with oncogenic signaling."	2.58	Metabolic reprogramming for cancer cells and their microenvironment: Beyond the Warburg Effect. ( Gao, P; Li, ST; Sun, L; Suo, C; Zhang, H, 2018)
"The presence of AnxA2 in cancer cell-derived exosomes, as well as the potential regulation of exosomal AnxA2 by phosphorylation or other PTMs, are topics of great interest."	2.55	Protein phosphorylation and its role in the regulation of Annexin A2 function. ( Grindheim, AK; Saraste, J; Vedeler, A, 2017)
"Many cancer cells are highly dependent on serine, a trait that provides several novel therapeutic opportunities, either through the inhibition of de novo serine synthesis or by limiting the availability or uptake of exogenous serine."	2.53	Serine and one-carbon metabolism in cancer. ( Vousden, KH; Yang, M, 2016)
"Relentless growth of cancer cells requires metabolic reprogramming that is intertwined with changes in the epigenetic landscape."	2.52	O-GlcNAc signaling in cancer metabolism and epigenetics. ( Singh, JP; Wu, J; Yang, X; Zhang, K, 2015)
"Also altered in cancer are components of the machinery which sense amino acid sufficiency, nucleated by the mechanistic target of rapamycin (mTOR), a key regulator of cell growth via modulation of key processes including protein synthesis and autophagy."	2.52	Amino acid management in cancer. ( Possemato, R; Tsun, ZY, 2015)
"The implications to anti-cancer medicine are highly significant, since these findings demonstrate that inhibiting one cell growth pathway may actually enhance the activity of alternative ones."	2.50	The STAT3-Ser/Hes3 signaling axis in cancer. ( Androutsellis-Theotokis, A; Park, DM; Poser, SW, 2014)
"Such effects were unrelated to cancer type."	2.43	Antineoplastic strategy: irreversible tumor blood flow stasis induced by the combretastatin A-4 derivative AVE8062 (AC7700). ( Hori, K, 2005)
"The chemoresistant tumors overexpress Bcl2/Bcl-xL/Mcl-1."	2.43	Posttranslational modifications of Bcl2 family members--a potential therapeutic target for human malignancy. ( Basu, A; DuBois, G; Haldar, S, 2006)
"How do cancer cells bolster their energy metabolism under conditions of stress? Recent work by Shu et al (2022) unveils a novel, non-canonical function of the de novo serine synthesis pathway enzyme phosphoglycerate dehydrogenase (PHGDH) as a regulator of mitochondrial translation and tumor progression in liver cancer."	1.91	PHGDH and cancer: new job for an old enzyme! ( Kuzuoglu-Ozturk, D, 2023)
"Furthermore, gLINC overexpression in cancer cells promotes xenograft growth in mice fed a diet deprived of serine, suggesting that cancer cells employ gLINC during metabolic reprogramming."	1.72	The long noncoding RNA glycoLINC assembles a lower glycolytic metabolon to promote glycolysis. ( De Souza, DP; Jin, L; Li, J; Liang, CZ; Narayana, VK; Shi, R; Thorne, RF; Wang, Y; Wu, M; Zhang, L; Zhang, LR; Zhang, XD; Zhu, Y, 2022)
"Our pancancer study provided a relatively comprehensive description of the carcinogenic effects of RIPK2 in different tumours, and provided useful information for further study of RIPK2."	1.72	A pancancer analysis of the carcinogenic role of receptor-interacting serine/threonine protein kinase-2 (RIPK2) in human tumours. ( Liu, R; Luo, H; Ma, Y; Wang, X; Zhang, H; Zhang, Q, 2022)
"GSK2830371 is a potent and selective allosteric inhibitor of PPM1D, but its mechanism of binding and inhibition of catalytic activity are unknown."	1.72	Allosteric inhibition of PPM1D serine/threonine phosphatase via an altered conformational state. ( Bajrami, B; Brousseau, M; Caliman, A; Campbell, AJ; Ebert, BL; Fischer, ES; Garvie, CW; Giacomelli, AO; Gibson, CJ; Guo, Q; Iqbal, S; Jiang, W; Jin, C; Kahn, J; Lintner, R; Miller, PG; Moroco, JA; Piccioni, F; Qian, Y; Raffier, C; Ranaghan, M; Root, DE; Sathappa, M; Shaw, S; Sperling, AS; Vernier, C; Yang, X, 2022)
"SPT is dispensable for cancer cell proliferation, as sphingolipids can be salvaged from the environment."	1.72	De novo sphingolipid biosynthesis necessitates detoxification in cancer cells. ( Armando, AM; Carlisle, AE; Doshi, MB; Gao, J; Greer, PL; Hwang, S; Kim, D; Lee, N; Li, R; Park, SJ; Quehenberger, O; Simin, K; Spears, ME; Torres, EM; Zhu, LJ, 2022)
"Here we demonstrate that cancer cells with loss of the retinoblastoma (RB) tumor suppressor became resistant to small molecule bromodomain inhibitors of BET proteins."	1.72	Retinoblastoma protein as an intrinsic BRD4 inhibitor modulates small molecule BET inhibitor sensitivity in cancer. ( Ding, D; Hou, X; Huang, H; Jimenez, R; Shi, L; Tian, Y; Wang, L; Weroha, SJ; Zheng, R, 2022)
"While many cancer cells cultured in a standard tissue culture medium depend on exogenous serine for optimal growth, here we report that these cells are less sensitive to serine/glycine depletion in medium containing physiological levels of metabolites."	1.62	The impact of physiological metabolite levels on serine uptake, synthesis and utilization in cancer cells. ( Cheung, EC; Driscoll, PC; Hennequart, M; Labuschagne, CF; Legrave, NM; Pilley, SE; Tajan, M; Vousden, KH, 2021)
"While PHGDH is often overexpressed in cancer cells, how it is regulated has been unclear."	1.56	Parkin on serine: a Parkinson disease gene suppresses serine synthesis in cancer. ( Dalton, WB, 2020)
"The therapeutic index of cytokines in cancer therapy can be increased by targeting strategies based on protein engineering with peptides containing the CNGRC (NGR) motif, a ligand that recognizes CD13-positive tumor vessels."	1.56	NGR-TNF Engineering with an N-Terminal Serine Reduces Degradation and Post-Translational Modifications and Improves Its Tumor-Targeting Activity. ( Colombo, B; Corti, A; Curnis, F; Ferreri, AJM; Gasparri, AM; Monieri, M; Rrapaj, E; Sacchi, A, 2020)
"A major hallmark of cancer is a perturbed metabolism resulting in high demand for various metabolites, glucose being the most well studied."	1.51	Analysis of glucose-derived amino acids involved in one-carbon and cancer metabolism by stable-isotope tracing gas chromatography mass spectrometry. ( Gu, W; Herring, J; Ou, Y; Sowers, ML; Tang, H; Zhang, K; Zhang, W, 2019)
"Many cancers upregulate expression of serine synthesis pathway enzymes, and some tumors exhibit copy-number gain of the gene encoding the first enzyme in the pathway, phosphoglycerate dehydrogenase (PHGDH)."	1.51	Increased Serine Synthesis Provides an Advantage for Tumors Arising in Tissues Where Serine Levels Are Limiting. ( Bosenberg, MW; Darnell, AM; Dennstedt, EA; Lewis, CA; Mattaini, KR; Meeth, K; Muir, A; Nguyen, AA; Reilly, MF; Sivanand, S; Sullivan, MR; Vander Heiden, MG, 2019)
"Here, using human cancer cells and patient-derived xenografts in mice, we show that the cyclin D3-CDK6 kinase phosphorylates and inhibits the catalytic activity of two key enzymes in the glycolytic pathway, 6-phosphofructokinase and pyruvate kinase M2."	1.46	The metabolic function of cyclin D3-CDK6 kinase in cancer cell survival. ( Chick, JM; Dyson, NJ; Gao, H; Gao, X; Geng, Y; Gerdemann, U; Gygi, SP; Haining, WN; Keibler, MA; Nicolay, BN; Polyak, K; Ren, H; Roberts, TM; Sicinska, E; Sicinski, P; Suski, JM; Wang, H; Williams, JA; Yang, G, 2017)
"Changes in cancer cell metabolism can directly impact epigenetic regulation and promote transformation."	1.43	Serine Metabolism Supports the Methionine Cycle and DNA/RNA Methylation through De Novo ATP Synthesis in Cancer Cells. ( Adams, PD; Labuschagne, CF; Maddocks, OD; Vousden, KH, 2016)
"Human ALT cancers show high mutation rates in ATRX and DAXX."	1.42	CHK1-driven histone H3.3 serine 31 phosphorylation is important for chromatin maintenance and cell survival in human ALT cancer cells. ( Chan, FL; Chang, FT; Collas, P; Mann, JR; Mayne, L; R McGhie, JD; Udugama, M; Wong, LH, 2015)
"Irinotecan has also displayed efficacy in clinical trials of NSCLC."	1.42	Topoisomerase-I PS506 as a Dual Function Cancer Biomarker. ( Gjerset, RA; Zhao, M, 2015)
"Our results define a role for PCK2 in cancer cell metabolic reprogramming that promotes glucose-independent cell growth and metabolic stress resistance in human tumors."	1.42	Mitochondrial Phosphoenolpyruvate Carboxykinase Regulates Metabolic Adaptation and Enables Glucose-Independent Tumor Growth. ( Artyomov, MN; Avizonis, D; Blagih, J; Bridon, G; Choinière, L; Coelho, PP; Elder, DJ; Flynn, BR; Gingras, MC; Griss, T; Jones, RG; Loginicheva, E; Ntimbane, T; Pause, A; Raissi, TC; Samborska, B; Sergushichev, A; Tavaré, JM; Thomas, EC; Vincent, EE, 2015)
"In lung cancer the anti-phospho-Ser522 signal is positive in squamous cell carcinoma more frequently than adenocarcinoma."	1.42	Phosphorylation of a splice variant of collapsin response mediator protein 2 in the nucleus of tumour cells links cyclin dependent kinase-5 to oncogenesis. ( Bray, SE; Carey, FA; Coates, PJ; Grant, NJ; Hastie, CJ; Lamont, DJ; Morrice, NA; Sutherland, C; Woods, YL, 2015)
"Previous work has shown that some cancer cells are highly dependent on serine/glycine uptake for proliferation."	1.40	Serine, but not glycine, supports one-carbon metabolism and proliferation of cancer cells. ( Labuschagne, CF; Mackay, GM; Maddocks, OD; van den Broek, NJ; Vousden, KH, 2014)
"Compared with the healthy group, lung cancer, cervical cancer, breast cancer and gastric cancer patients with abnormal Savda had lower concentration of plasma amino acids except some amino acids."	1.40	[Plasma amino acid profiling of "same symptom for different disease" in Uyghur medicine based on high-performance liquid chromatography]. ( Eli, M; Kong, B; Mamtimin, B; Turahun, A; Upur, H, 2014)
"Reduced growth of tumors composed of cells expressing the nonphosphorylatable KRAS S181A mutant was correlated with increased apoptosis."	1.40	Phosphorylation at Ser-181 of oncogenic KRAS is required for tumor growth. ( Agell, N; Alvarez-Moya, B; Barceló, C; Bota-Rabassedas, N; Capella, G; Jaumot, M; Morell, M; Paco, N; Vilardell, F, 2014)
"Recent observations on cancer cell metabolism indicate increased serine synthesis from glucose as a marker of poor prognosis."	1.39	Contribution of serine, folate and glycine metabolism to the ATP, NADPH and purine requirements of cancer cells. ( Bertino, JR; Boros, LG; Chan, LL; DiPaola, RS; Dolfi, SC; Dvorzhinski, D; Gounder, M; Hirshfield, KM; Lin, H; Markert, EK; Oltvai, ZN; Qiu, J; Tedeschi, PM; Vazquez, A, 2013)
"We propose that patients whose tumors show this phenotype will be sensitive to folate antagonists targeting thymidylate or purine biosynthesis."	1.39	Overexpression of the mitochondrial folate and glycine-serine pathway: a new determinant of methotrexate selectivity in tumors. ( Bertino, JR; Tedeschi, PM; Vazquez, A, 2013)
"Here we show that human cancer cells rapidly use exogenous serine and that serine deprivation triggered activation of the serine synthesis pathway and rapidly suppressed aerobic glycolysis, resulting in an increased flux to the tricarboxylic acid cycle."	1.39	Serine starvation induces stress and p53-dependent metabolic remodelling in cancer cells. ( Berkers, CR; Blyth, K; Gottlieb, E; Maddocks, OD; Mason, SM; Vousden, KH; Zheng, L, 2013)
"TICs from primary NSCLC tumors express high levels of the oncogenic stem cell factor LIN28B and GLDC, which are both required for TIC growth and tumorigenesis."	1.38	Glycine decarboxylase activity drives non-small cell lung cancer tumor-initiating cells and tumorigenesis. ( Ahmed, DA; Ang, HS; Bhakoo, KK; Jayapal, SR; Kaldis, P; Lim, B; Lim, EH; Ma, S; Mitchell, W; Nga, ME; Nichane, M; Noghabi, MS; Pang, YH; Rai, A; Robson, P; Shyh-Chang, N; Sing, WP; Soh, BS; Soo, RA; Sun, LL; Swarup, S; Tai, BC; Tam, J; Tan, C; Thirugananam, A; Umashankar, S; Yang, H; Yu, Q; Zhang, WC, 2012)
" Close collaboration with cardiology colleagues for early indicators of serious cardiac adverse events will likely minimize toxicity while optimizing the therapeutic potential of VDAs and ultimately enhancing patient outcomes."	1.37	Cardiovascular toxicity profiles of vascular-disrupting agents. ( Lenihan, DJ; Subbiah, IM; Tsimberidou, AM, 2011)
"In this study, the anticancer immunity of CCL-34 was further demonstrated."	1.37	In vitro and in vivo anticancer activity of a synthetic glycolipid as Toll-like receptor 4 (TLR4) activator. ( Chen, YJ; Fu, SL; Huang, LD; Huang, PH; Lin, CC; Lin, CH; Lin, YS; Wong, FH, 2011)
"PKB is upregulated in many different cancers and a significant amount of the enzyme is present in its activated form."	1.36	PKB/AKT phosphorylation of the transcription factor Twist-1 at Ser42 inhibits p53 activity in response to DNA damage. ( Gresko, E; Hemmings, BA; Hess, D; Restuccia, DF; Vichalkovski, A, 2010)
"However, many cancer cells are resistant to TRAIL, suggesting the mechanism mediating TRAIL-induced apoptosis is complex."	1.35	Akt and 14-3-3 control a PACS-2 homeostatic switch that integrates membrane traffic with TRAIL-induced apoptosis. ( Aslan, JE; Brush, MH; Du, Y; Endig, J; Fu, H; Greis, KD; Milewski, RL; Possemato, A; Runckel, DN; Shu, H; Sprott, K; Thomas, G; Thomas, L; Vogel, A; Williamson, DM; You, H; Youker, RT, 2009)
"Cell adhesion is a critical step in cancer metastasis, activated by extracellular forces such as pressure and shear."	1.35	Identification of functional domains in AKT responsible for distinct roles of AKT isoforms in pressure-stimulated cancer cell adhesion. ( Basson, MD; Wang, S, 2008)
"We found that aggressive head and neck cancers exhibited overexpression and stabilization of Aur-A protein without gene amplification or mRNA overexpression."	1.34	Constitutive phosphorylation of aurora-a on ser51 induces its stabilization and consequent overexpression in cancer. ( Kawai, H; Kitajima, S; Kudo, Y; Ogawa, I; Pagano, M; Takata, T; Tatsuka, M, 2007)
"Interestingly, in certain types of cancers (e."	1.34	Identification of S664 TSC2 phosphorylation as a marker for extracellular signal-regulated kinase mediated mTOR activation in tuberous sclerosis and human cancer. ( Bernardi, R; Bonner, P; Cordon-Cardo, C; Franz, DN; Ma, L; Pandolfi, PP; Teruya-Feldstein, J; Witte, D, 2007)
"While p53(S18A) mice are not cancer prone, p53S18/23A mice developed a spectrum of malignancies distinct from p53S23A and p53(-/-) mice."	1.33	Ser18 and 23 phosphorylation is required for p53-dependent apoptosis and tumor suppression. ( Chao, C; Chun, J; Herr, D; Xu, Y, 2006)
"More than half of human cancers contain mutations in the tumor suppressor protein p53, most of which accumulate in the DNA binding domain of the protein."	1.33	Identification of p53-46F as a super p53 with an enhanced ability to induce p53-dependent apoptosis. ( Arakawa, H; Futamura, M; Kamino, H; Nakamura, Y; Yoshida, K, 2006)
"However, hypoxia within tumors is often transient and is inevitably followed by reoxygenation."	1.32	ATR/ATM targets are phosphorylated by ATR in response to hypoxia and ATM in response to reoxygenation. ( Dorie, MJ; Giaccia, AJ; Hammond, EM, 2003)
"Induction of apoptosis in cancer cells by anti-cancer drugs and biosynthetic inhibitors of cells surface glycolipids in the human colon carcinoma cells (Colo-205) are of interest in recent years."	1.32	Apoptosis of human carcinoma cells in the presence of inhibitors of glycosphingolipid biosynthesis: I. Treatment of Colo-205 and SKBR3 cells with isomers of PDMP and PPMP. ( Banerjee, S; Basu, M; Basu, S; Bradley, M; Inokuchi, J; Ma, R; Mikulla, B; Moulton, C, 2004)

Timeframe	Studies, this research(%)	All Research%
pre-1990	35 (13.83)	18.7374
1990's	7 (2.77)	18.2507
2000's	43 (17.00)	29.6817
2010's	113 (44.66)	24.3611
2020's	55 (21.74)	2.80

Trial	Phase	Enrollment	Study Type	Start Date	Status
An Open-label, Dose Escalation, Safety and Pharmacokinetics Phase 1 Study With AVE8062 Administered as a 30-minute Intravenous Infusion Every 3 Weeks in Patients With Advanced Solid Tumors.[NCT00968916]	Phase 1	15 participants (Actual)	Interventional	2009-09-30	Completed
An Open Label, Dose Escalation, Safety and Pharmacokinetic Phase 1 Study With AVE8062 Administered as a 30 Minutes Intravenous Infusion Followed by Docetaxel Administered as an 1 Hour Intravenous Infusion 24 Hours-Apart Every 3 Weeks in Patients With Adva[NCT01907685]	Phase 1	58 participants (Actual)	Interventional	2006-06-30	Completed
An Open-label, Non-randomized, Dose Evaluation, Safety and Pharmacokinetics Phase I Study of AVE8062 in Combination With Platinum Salts (Cisplatin or Carboplatin) and Taxanes (Docetaxel or Paclitaxel), Every 3 Weeks, in Patients With Advanced Solid Tumors[NCT00719524]	Phase 1	71 participants (Actual)	Interventional	2008-07-31	Completed
A Pilot Study of Nintedanib for LymphAngioleioMyomatosis (LAM)[NCT03062943]	Phase 2	30 participants (Actual)	Interventional	2016-12-06	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Article	Year
Phosphatases of regenerating liver are key regulators of metabolism in cancer cells - role of Serine/Glycine metabolism. Current opinion in clinical nutrition and metabolic care, 2022, 01-01, Volume: 25, Issue:1 Topics: Glycine; Humans; Liver; Neoplasms; Protein Tyrosine Phosphatases; Serine	2022
The NEK family of serine/threonine kinases as a biomarker for cancer. Clinical and experimental medicine, 2023, Volume: 23, Issue:1 Topics: Biomarkers; Cell Cycle Proteins; Humans; Neoplasms; NIMA-Related Kinases; Protein Serine-Threonine K	2023
Current status of cancer starvation therapy. Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences, 2022, Apr-25, Volume: 51, Issue:2 Topics: Amino Acids; Angiogenesis Inhibitors; Glycine; Humans; Integrins; Neoplasms; Serine	2022
Serine-Arginine Protein Kinase 1 (SRPK1): a systematic review of its multimodal role in oncogenesis. Molecular and cellular biochemistry, 2022, Volume: 477, Issue:10 Topics: Arginine; Arginine Kinase; Carcinogenesis; Cell Transformation, Neoplastic; Humans; Neoplasms; NF-ka	2022
Unfolding the cascade of SERPINA3: Inflammation to cancer. Biochimica et biophysica acta. Reviews on cancer, 2022, Volume: 1877, Issue:5 Topics: Acute-Phase Proteins; Biomarkers, Tumor; Carcinogens; Humans; Inflammation; Neoplasms; Serine; Serin	2022
Microtubule-affinity regulating kinase 4: A potential drug target for cancer therapy. Cellular signalling, 2022, Volume: 99 Topics: Adenosine Triphosphate; AMP-Activated Protein Kinases; Humans; Microtubules; Neoplasms; Neurodegener	2022
The role of mixed lineage kinase 3 (MLK3) in cancers. Pharmacology & therapeutics, 2022, Volume: 238 Topics: Humans; MAP Kinase Kinase Kinases; Mitogen-Activated Protein Kinase Kinase Kinase 11; Neoplasms; Pro	2022
A patent and literature review of CDK12 inhibitors. Expert opinion on therapeutic patents, 2022, Volume: 32, Issue:10 Topics: Animals; Cyclin-Dependent Kinases; Cyclins; Humans; Mice; Myotonic Dystrophy; Neoplasms; Patents as	2022
An update regarding the role of WNK kinases in cancer. Cell death & disease, 2022, 09-19, Volume: 13, Issue:9 Topics: Alanine; Animals; Bicarbonates; Mammals; Neoplasms; Neovascularization, Pathologic; Proline; Serine;	2022
SR Splicing Factors Promote Cancer via Multiple Regulatory Mechanisms. Genes, 2022, 09-16, Volume: 13, Issue:9 Topics: Arginine; Humans; Neoplasms; RNA; RNA Splicing Factors; RNA-Binding Proteins; Serine; Serine-Arginin	2022
Target enzymes in serine-glycine-one-carbon metabolic pathway for cancer therapy. International journal of cancer, 2023, 06-15, Volume: 152, Issue:12 Topics: Carbon; Carcinogenesis; Glycine; Humans; Metabolic Networks and Pathways; Neoplasms; Serine	2023
Serine Metabolic Reprogramming in Tumorigenesis, Tumor Immunity, and Clinical Treatment. Advances in nutrition (Bethesda, Md.), 2023, Volume: 14, Issue:5 Topics: Carcinogenesis; Humans; Neoplasms; Proteins; Serine	2023
Mission Possible: Advances in MYC Therapeutic Targeting in Cancer. BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy, 2019, Volume: 33, Issue:5 Topics: Animals; Antineoplastic Agents; Gene Expression Regulation, Neoplastic; Genes, myc; Humans; Molecula	2019
The complexity of the serine glycine one-carbon pathway in cancer. The Journal of cell biology, 2020, 01-06, Volume: 219, Issue:1 Topics: Animals; Carbon; Glycine; Humans; Metabolic Networks and Pathways; Neoplasms; Serine	2020
The Role of D-3-Phosphoglycerate Dehydrogenase in Cancer. International journal of biological sciences, 2020, Volume: 16, Issue:9 Topics: Antineoplastic Agents; Drug Resistance, Neoplasm; Enzyme Inhibitors; Gene Expression Regulation, Neo	2020
Reprogramming of serine, glycine and one-carbon metabolism in cancer. Biochimica et biophysica acta. Molecular basis of disease, 2020, 10-01, Volume: 1866, Issue:10 Topics: Animals; Carbon; Cellular Reprogramming; Glycine; Humans; Metabolic Networks and Pathways; Methionin	2020
Therapeutic Targeting of Mitochondrial One-Carbon Metabolism in Cancer. Molecular cancer therapeutics, 2020, Volume: 19, Issue:11 Topics: Aminohydrolases; Animals; Antineoplastic Agents; Biomarkers; Carbon; Energy Metabolism; Gene Express	2020
Rebelled epigenome: histone H3S10 phosphorylation and H3S10 kinases in cancer biology and therapy. Clinical epigenetics, 2020, 10-14, Volume: 12, Issue:1 Topics: Biology; Carcinogenesis; Chromatin; Clinical Trials as Topic; DNA Methylation; Epigenesis, Genetic;	2020
LKB1 deficiency-induced metabolic reprogramming in tumorigenesis and non-neoplastic diseases. Molecular metabolism, 2021, Volume: 44 Topics: AMP-Activated Protein Kinase Kinases; AMP-Activated Protein Kinases; Animals; Apoptosis; Carcinogene	2021
Serine, glycine and one‑carbon metabolism in cancer (Review). International journal of oncology, 2021, Volume: 58, Issue:2 Topics: Animals; Antineoplastic Agents; Carbon; Carcinogenesis; Disease Models, Animal; Glycine; Humans; Met	2021
The ins and outs of serine and glycine metabolism in cancer. Nature metabolism, 2021, Volume: 3, Issue:2 Topics: Animals; Glycine; Humans; Neoplasms; Serine	2021
Serine and Functional Metabolites in Cancer. Trends in cell biology, 2017, Volume: 27, Issue:9 Topics: Animals; Carbon; Cell Proliferation; Humans; Neoplasms; Serine	2017
Protein phosphorylation and its role in the regulation of Annexin A2 function. Biochimica et biophysica acta. General subjects, 2017, Volume: 1861, Issue:11 Pt A Topics: Annexin A2; Cell Transformation, Neoplastic; Exosomes; Gene Expression Regulation, Neoplastic; Human	2017
Bad phosphorylation as a target of inhibition in oncology. Cancer letters, 2018, 02-28, Volume: 415 Topics: Apoptosis; bcl-Associated Death Protein; Cell Survival; Disease Progression; Humans; Neoplasms; Phos	2018
Metabolic reprogramming for cancer cells and their microenvironment: Beyond the Warburg Effect. Biochimica et biophysica acta. Reviews on cancer, 2018, Volume: 1870, Issue:1 Topics: Amino Acids, Branched-Chain; Cell Proliferation; Humans; Neoplasms; Nutrients; Pentose Phosphate Pat	2018
Serine and one-carbon metabolism, a bridge that links mTOR signaling and DNA methylation in cancer. Pharmacological research, 2019, Volume: 149 Topics: Animals; DNA Methylation; Epigenesis, Genetic; Gene Expression Regulation, Neoplastic; Humans; Neopl	2019
Interstitial collagen catabolism. The Journal of biological chemistry, 2013, Mar-29, Volume: 288, Issue:13 Topics: Animals; Arthritis; Binding Sites; Catalysis; Cathepsin K; Collagen; Gene Expression Regulation, Enz	2013
SRp20: an overview of its role in human diseases. Biochemical and biophysical research communications, 2013, Jun-21, Volume: 436, Issue:1 Topics: Alternative Splicing; Amino Acid Sequence; Arginine; Gene Expression Regulation, Neoplastic; Humans;	2013
Serine, glycine and one-carbon units: cancer metabolism in full circle. Nature reviews. Cancer, 2013, Volume: 13, Issue:8 Topics: Epigenesis, Genetic; Glycine; Humans; Methylation; Neoplasms; Oxidation-Reduction; Serine	2013
The STAT3-Ser/Hes3 signaling axis in cancer. Frontiers in bioscience (Landmark edition), 2014, 01-01, Volume: 19, Issue:4 Topics: DNA-Binding Proteins; Humans; Neoplasms; Repressor Proteins; Serine; Signal Transduction; STAT3 Tran	2014
Serine and glycine metabolism in cancer. Trends in biochemical sciences, 2014, Volume: 39, Issue:4 Topics: Cell Proliferation; Glycine; Humans; Metabolic Networks and Pathways; Neoplasms; Serine	2014
O-GlcNAc signaling in cancer metabolism and epigenetics. Cancer letters, 2015, Jan-28, Volume: 356, Issue:2 Pt A Topics: Acetylglucosamine; Antigens, Neoplasm; Cell Proliferation; Energy Metabolism; Epigenesis, Genetic; G	2015
[Isotopic tracing technique in quantitative analysis of metabolic reprogramming in tumor cells]. Se pu = Chinese journal of chromatography, 2015, Volume: 33, Issue:2 Topics: Carbon Isotopes; Cell Line, Tumor; Citric Acid Cycle; Glutamine; Humans; Isotope Labeling; Mass Spec	2015
Amino acid management in cancer. Seminars in cell & developmental biology, 2015, Volume: 43 Topics: Citric Acid Cycle; Glutamine; Humans; Neoplasms; Protein Biosynthesis; Serine; Signal Transduction;	2015
Give it or take it: the flux of one-carbon in cancer cells. The FEBS journal, 2016, Volume: 283, Issue:20 Topics: Animals; Carbon; Carbon Cycle; Cell Compartmentation; Cytosol; Embryonic Development; Glycine; Human	2016
The importance of serine metabolism in cancer. The Journal of cell biology, 2016, 08-01, Volume: 214, Issue:3 Topics: Animals; Biosynthetic Pathways; Humans; Models, Biological; Neoplasms; Nucleotides; Phosphoglycerate	2016
Serine and one-carbon metabolism in cancer. Nature reviews. Cancer, 2016, Volume: 16, Issue:10 Topics: Cell Proliferation; Humans; Neoplasms; Serine	2016
Challenges and Opportunities in the Development of Serine Synthetic Pathway Inhibitors for Cancer Therapy. Journal of medicinal chemistry, 2017, 02-23, Volume: 60, Issue:4 Topics: Animals; Antineoplastic Agents; Biosynthetic Pathways; Drug Discovery; Enzyme Inhibitors; Glucose; H	2017
Non-canonical Activation of Receptor Tyrosine Kinases in Cancer Progression. Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan, 2017, Volume: 137, Issue:2 Topics: Antineoplastic Agents; Cell Movement; Cell Proliferation; Disease Progression; Drug Resistance, Neop	2017
AVE8062: a new combretastatin derivative vascular disrupting agent. Expert opinion on investigational drugs, 2009, Volume: 18, Issue:10 Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Clinical Trials as Topic; Drug Evaluation,	2009
[Advances in the study of the anti-tumor activity of small molecule vascular disrupting agents]. Yao xue xue bao = Acta pharmaceutica Sinica, 2010, Volume: 45, Issue:3 Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Bibenzyls; Diphosphates; Endothelial Cells;	2010
Vascular disrupting agents (VDA) in oncology: advancing towards new therapeutic paradigms in the clinic. Current drug targets, 2011, Volume: 12, Issue:14 Topics: Angiogenesis Inhibitors; Blood Vessels; Clinical Trials as Topic; Diketopiperazines; Humans; Neoplas	2011
Antineoplastic strategy: irreversible tumor blood flow stasis induced by the combretastatin A-4 derivative AVE8062 (AC7700). Chemotherapy, 2005, Volume: 51, Issue:6 Topics: Animals; Antineoplastic Agents; Microcirculation; Neoplasms; Rats; Regional Blood Flow; Serine; Stil	2005
Posttranslational modifications of Bcl2 family members--a potential therapeutic target for human malignancy. Frontiers in bioscience : a journal and virtual library, 2006, May-01, Volume: 11 Topics: Alanine; Animals; Apoptosis; bcl-X Protein; Cell Death; Cytoplasm; DNA, Complementary; Humans; Mice;	2006
Role of IFI16 in DNA damage and checkpoint. Frontiers in bioscience : a journal and virtual library, 2008, Jan-01, Volume: 13 Topics: Cell Cycle; Cyclin-Dependent Kinase Inhibitor p21; DNA Damage; Humans; Models, Biological; Neoplasms	2008
Mutant p53: "gain of function" through perturbation of nuclear structure and function? Journal of cellular biochemistry. Supplement, 2000, Volume: Suppl 35 Topics: Animals; Cell Nucleus; DNA; Genes, p53; Humans; Models, Genetic; Mutation; Neoplasms; Phenotype; Pro	2000
Anticoagulation: the present and future. Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis, 2001, Volume: 7, Issue:3 Topics: Administration, Oral; Amino Acid Chloromethyl Ketones; Anticoagulants; Arginine; Azetidines; Benzyla	2001

Article	Year
Phase I safety, pharmacokinetic and pharmacodynamic evaluation of the vascular disrupting agent ombrabulin (AVE8062) in patients with advanced solid tumors. Clinical cancer research : an official journal of the American Association for Cancer Research, 2013, Sep-01, Volume: 19, Issue:17 Topics: Adult; Aged; Biomarkers, Tumor; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug	2013
An open-label, dose-escalation, safety, and pharmacokinetics phase I study of ombrabulin, a vascular disrupting agent, administered as a 30-min intravenous infusion every 3 weeks in Japanese patients with advanced solid tumors. Cancer chemotherapy and pharmacology, 2014, Volume: 73, Issue:3 Topics: Asian People; Cohort Studies; Dose-Response Relationship, Drug; Drug Administration Schedule; Female	2014
A phase I pharmacokinetic study of the vascular disrupting agent ombrabulin (AVE8062) and docetaxel in advanced solid tumours. British journal of cancer, 2014, Apr-29, Volume: 110, Issue:9 Topics: Adolescent; Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Do	2014
Phase I clinical and pharmacokinetic study of ombrabulin (AVE8062) combined with cisplatin/docetaxel or carboplatin/paclitaxel in patients with advanced solid tumors. Investigational new drugs, 2014, Volume: 32, Issue:6 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Docetaxel; Drug	2014

serine and Neoplasms

Research Excerpts

Research

Studies (253)

Authors

Clinical Trials (4)

Trial Overview

Reviews

Trials

Other Studies

Authors	Studies
Li, X	3
Gracilla, D	1
Cai, L	1
Zhang, M	1
Yu, X	1
Chen, X	2
Zhang, J	5
Long, X	1
Ding, HF	1
Yan, C	1
Hennequart, M	2
Labuschagne, CF	4
Tajan, M	2
Pilley, SE	1
Cheung, EC	2
Legrave, NM	1
Driscoll, PC	1
Vousden, KH	7
Abdollahi, P	1
Vandsemb, EN	1
Børset, M	1
Panchal, NK	1
Evan Prince, S	1
Zhu, Y	2
Jin, L	1
Shi, R	1
Li, J	2
Wang, Y	5
Zhang, L	2
Liang, CZ	1
Narayana, VK	1
De Souza, DP	1
Thorne, RF	1
Zhang, LR	1
Zhang, XD	1
Wu, M	4
Tong, D	1
Lin, J	1
Zhang, H	6
Ma, Y	2
Zhang, Q	4
Liu, R	2
Luo, H	1
Wang, X	3
Duggan, WP	1
O'Connell, E	1
Prehn, JHM	1
Burke, JP	1
Makino, Y	1
Oe, C	1
Iwama, K	1
Suzuki, S	1
Nishiyama, A	1
Hasegawa, K	1
Okuda, H	1
Hirata, K	1
Ueno, M	1
Kawaji, K	1
Sasano, M	1
Usui, E	1
Hosaka, T	1
Yabuki, Y	1
Shirouzu, M	1
Katsumi, M	1
Murayama, K	1
Hayashi, H	2
Kodama, EN	1
Miller, PG	1
Sathappa, M	1
Moroco, JA	1
Jiang, W	1
Qian, Y	1
Iqbal, S	1
Guo, Q	2
Giacomelli, AO	1
Shaw, S	1
Vernier, C	1
Bajrami, B	1
Yang, X	4
Raffier, C	1
Sperling, AS	1
Gibson, CJ	1
Kahn, J	1
Jin, C	1
Ranaghan, M	1
Caliman, A	1
Brousseau, M	1
Fischer, ES	1
Lintner, R	1
Piccioni, F	1
Campbell, AJ	1
Root, DE	1
Garvie, CW	1
Ebert, BL	1
Liu, Y	4
Qi, X	1
Donnelly, L	1
Elghobashi-Meinhardt, N	1
Long, T	1
Zhou, RW	1
Sun, Y	1
Wang, B	2
Soman, A	1
Asha Nair, S	1
Anwar, S	1
Shahwan, M	1
Hasan, GM	1
Islam, A	1
Hassan, MI	1
Pranzini, E	1
Pardella, E	1
Muccillo, L	1
Leo, A	1
Nesi, I	1
Santi, A	1
Parri, M	1
Zhang, T	3
Uribe, AH	1
Lottini, T	1
Sabatino, L	1
Caselli, A	1
Arcangeli, A	1
Raugei, G	1
Colantuoni, V	1
Cirri, P	1
Chiarugi, P	1
Maddocks, ODK	5
Paoli, P	1
Taddei, ML	1
Ramachandraiah, K	1
Thylur Puttalingaiah, R	1
Shi, Q	1
Shen, Q	1
Shi, Y	2
Huang, W	2
Li, Z	1
Chai, Y	1
Wang, H	5
Hu, X	1
Li, N	2
Cao, X	1
McClellan, B	1
Gries, P	1
Harlow, B	1
Tiziani, S	1
Jolly, C	1
deGraffenried, L	1
Cordes, T	2
Kuna, RS	1
McGregor, GH	1
Khare, SV	1
Gengatharan, J	2
Muthusamy, T	2
Metallo, CM	3
Tang, R	1
Liu, J	2
Li, S	1
Yu, C	1
Liu, H	1
Chen, F	1
Lv, L	1
Yuan, K	1
Shao, H	1
Xiu, M	1
Li, L	2
Li, Y	3
Gao, Y	1
Wan, L	1
Deng, M	1
Sadiqa, A	1
Rasul, A	1
Hassan, M	1
Sultana, S	1
Jabeen, F	1
Spears, ME	1
Lee, N	1
Hwang, S	1
Park, SJ	1
Carlisle, AE	1
Li, R	2
Doshi, MB	1
Armando, AM	1
Gao, J	1
Simin, K	1
Zhu, LJ	1
Greer, PL	1
Quehenberger, O	1
Torres, EM	1
Kim, D	1
Drozdz, MM	1
Doane, AS	1
Alkallas, R	1
Desman, G	1
Bareja, R	1
Reilly, M	1
Bang, J	1
Yusupova, M	1
You, J	1
Eraslan, Z	1
Wang, JZ	1
Verma, A	1
Aguirre, K	1
Kane, E	1
Watson, IR	1
Elemento, O	1
Piskounova, E	1
Merghoub, T	1
Zippin, JH	1
Almilaibary, A	1
Ding, D	1
Zheng, R	1
Tian, Y	1
Jimenez, R	1
Hou, X	1
Weroha, SJ	1
Wang, L	1
Shi, L	1
Huang, H	1
Sun, W	1
Zhao, E	1
Cui, H	1
Kuzuoglu-Ozturk, D	2
Gao, D	1
Tang, S	2
Cen, Y	1
Yuan, L	1
Lan, X	2
Li, QH	1
Lin, GQ	1
Huang, M	3
Tian, P	1
Yoon, SJ	1
Combs, JA	1
Falzone, A	1
Prieto-Farigua, N	1
Caldwell, S	1
Ackerman, HD	1
Flores, ER	1
DeNicola, GM	2
Shunxi, W	1
Xiaoxue, Y	1
Guanbin, S	1
Junyu, J	1
Wanqian, L	1
Fang, Z	1
Song, C	1
Allen-Petersen, BL	1
Sears, RC	1
Dalton, WB	2
Helmenstine, E	1
Walsh, N	1
Gondek, LP	1
Kelkar, DS	1
Read, A	1
Natrajan, R	1
Christenson, ES	1
Roman, B	1
Das, S	1
Zhao, L	1
Leone, RD	1
Shinn, D	1
Groginski, T	1
Madugundu, AK	1
Patil, A	1
Zabransky, DJ	1
Medford, A	1
Lee, J	1
Cole, AJ	1
Rosen, M	1
Thakar, M	1
Ambinder, A	1
Donaldson, J	1
DeZern, AE	1
Cravero, K	1
Chu, D	1
Madero-Marroquin, R	1
Pandey, A	1
Hurley, PJ	1
Lauring, J	1
Park, BH	1
Zhu, J	1
Berisa, M	1
Schwörer, S	1
Qin, W	2
Cross, JR	2
Thompson, CB	3
Reina-Campos, M	1
Diaz-Meco, MT	1
Moscat, J	1
Cheng, A	1
Zhang, P	1
Yang, D	2
Duan, X	1
Jiang, Y	2
Xu, T	1
Shi, J	1
Ding, C	2
Wu, G	1
Sang, Z	1
Wu, Q	1
Zhang, Z	2
Pan, X	1
Pan, YY	1
Gao, P	3
Zhou, CZ	1
Guo, J	1
Yang, Z	2
Li, AM	2
Ye, J	3
Zhao, X	2
Fu, J	1
Du, J	1
Xu, W	2
Uehara, T	1
Sensui, A	1
Ishioka, S	1
Mizuno, Y	1
Takahashi, S	1
Takemori, H	1
Suzuki, H	1
Arano, Y	1
Ye, S	1
Xu, P	1
Zeng, S	1
Wang, Q	2
Chen, J	3
Li, K	1
Gao, W	1
Shao, Y	1
Xu, Y	2
Zhong, Z	1
Wei, Z	1
Wang, J	1
Hao, B	1
Liu, Q	1
Baumann, K	1
Haensel, D	1
Oro, AE	1
Shrestha, A	1
Bruckmueller, H	1
Kildalsen, H	1
Kaur, G	1
Gaestel, M	1
Wetting, HL	1
Mikkola, I	1
Seternes, OM	1
Handzlik, MK	1
You, L	1
Lim, EW	1
Pinto, AFM	1
Badur, MG	1
Kolar, MJ	1
Wallace, M	1
Saghatelian, A	1
Corti, A	1
Gasparri, AM	1
Sacchi, A	1
Colombo, B	1
Monieri, M	1
Rrapaj, E	1
Ferreri, AJM	1
Curnis, F	1
Dekhne, AS	1
Hou, Z	1
Gangjee, A	1
Matherly, LH	1
Dotsenko, O	1
Shtofel, D	1
Komar, D	1
Juszczynski, P	1
Falcone, M	1
Zhang, Y	2
Meng, Q	1
Sun, Q	2
Xu, ZX	1
Zhou, H	1
Zani, F	1
Hock, AK	1
Legrave, N	1
Ridgway, RA	1
Athineos, D	1
Suárez-Bonnet, A	1
Ludwig, RL	1
Novellasdemunt, L	1
Angelis, N	1
Li, VSW	1
Vlachogiannis, G	1
Valeri, N	1
Mainolfi, N	1
Suri, V	1
Friedman, A	1
Manfredi, M	1
Blyth, K	2
Sansom, OJ	1
Pan, S	1
Fan, M	1
Liu, Z	3
Geeraerts, SL	1
Heylen, E	1
De Keersmaecker, K	1
Kampen, KR	1
Cheng, F	1
Zhao, J	1
Lu, W	1
Zhou, Y	3
Martin, WR	1
Wang, R	1
Huang, J	1
Hao, T	1
Yue, H	1
Ma, J	1
Hou, Y	1
Castrillon, JA	1
Fang, J	1
Lathia, JD	1
Keri, RA	1
Lightstone, FC	1
Antman, EM	1
Rabadan, R	1
Hill, DE	1
Eng, C	1
Vidal, M	1
Loscalzo, J	1
Prokhorova, E	1
Zobel, F	1
Smith, R	1
Zentout, S	1
Gibbs-Seymour, I	1
Schützenhofer, K	1
Peters, A	1
Groslambert, J	1
Zorzini, V	1
Agnew, T	1
Brognard, J	1
Nielsen, ML	1
Ahel, D	1
Huet, S	1
Suskiewicz, MJ	1
Ahel, I	1
Buqué, A	1
Galluzzi, L	1
Montrose, DC	1
Gilmour, R	1
Velasco, S	1
Sullivan, MR	3
Vander Heiden, MG	3
Amelio, I	3
Melino, G	3
Frezza, C	2
Newman, AC	2
Nicolay, BN	2
Chick, JM	1
Gao, X	1
Geng, Y	1
Ren, H	1
Gao, H	1
Yang, G	1
Williams, JA	1
Suski, JM	1
Keibler, MA	1
Sicinska, E	1
Gerdemann, U	1
Haining, WN	1
Roberts, TM	1
Polyak, K	1
Gygi, SP	1
Dyson, NJ	1
Sicinski, P	1
Grindheim, AK	1
Saraste, J	1
Vedeler, A	1
Zhang, F	1
Virshup, DM	2
Cheong, JK	1
Peng, C	1
Zhang, W	2
Liao, Q	1
Chen, Y	1
Shen, P	1
Zhen, B	1
Qian, X	1
Zhang, JS	1
Xiao, D	1
Pei, H	1
Bui, NL	1
Pandey, V	1
Zhu, T	1
Ma, L	3
Lobie, PE	1
Jusu, S	1
Presley, JF	1
Williams, C	1
Das, SK	1
Jean-Claude, B	1
Kremer, R	1
Shin, H	1
Cha, HJ	1
Na, K	1
Lee, MJ	1
Cho, JY	1
Kim, CY	1
Kim, EK	1
Kang, CM	1
Kim, H	1
Paik, YK	1
Krishnamoorthy, J	1
Tenkerian, C	1
Gupta, J	1
Ghaddar, N	1
Wang, S	2
Darini, C	1
Staschke, KA	1
Ghosh, A	1
Gandin, V	1
Topisirovic, I	2
Kristof, AS	1
Hatzoglou, M	1
Simos, G	1
Koromilas, AE	1
Storchová, Z	1
Sun, L	1
Suo, C	1
Li, ST	1
Sowers, ML	1
Herring, J	1
Tang, H	1
Ou, Y	1
Gu, W	1
Zhang, K	2
Dubbury, SJ	1
Boutz, PL	1
Sharp, PA	1
Chen, H	1
Yu, D	1
Fang, R	1
Rabidou, K	1
Wu, D	1
Hu, D	1
Jia, P	1
Zhao, Z	1
Wu, Z	2
Peng, J	1
Shi, YG	1
Seibert, M	1
Krüger, M	1
Watson, NA	1
Sen, O	1
Daum, JR	1
Slotman, JA	1
Braun, T	1
Houtsmuller, AB	1
Gorbsky, GJ	1
Jacob, R	1
Kracht, M	1
Higgins, JMG	1
Schmitz, ML	1
Mu, Y	1
Li, W	1
Zhou, L	1
Lu, X	3
Gao, M	1
Zhao, Y	2
Xu, G	1
Mattaini, KR	2
Dennstedt, EA	1
Nguyen, AA	1
Sivanand, S	1
Reilly, MF	1
Meeth, K	1
Muir, A	1
Darnell, AM	1
Bosenberg, MW	1
Lewis, CA	1
Szybowska, P	1
Kostas, M	1
Wesche, J	1
Wiedlocha, A	1
Haugsten, EM	1
Jin, N	1
Bi, A	1
Xu, J	2
Wang, T	2
Zeng, H	1
Chen, Z	2
Tan, M	1
Ai, J	1
Xie, H	1
Liu, D	1
Huang, R	1
Song, Y	1
Leung, EL	1
Yao, X	1
Ding, J	1
Geng, M	1
Lin, SH	1
Zeng, JD	1
Wu, WKK	1
Wang, HY	1
Li, XX	1
Tang, J	1
Agrawal, T	1
Cheng, Q	1
Qu, L	1
Brewer, MD	1
Fields, GB	1
Nieminen, AI	1
Eskelinen, VM	1
Haikala, HM	1
Tervonen, TA	1
Yan, Y	1
Partanen, JI	1
Klefström, J	1
Corbo, C	1
Orrù, S	1
Salvatore, F	1
Locasale, JW	3
Sessa, C	3
Lorusso, P	2
Tolcher, A	1
Farace, F	1
Lassau, N	2
Delmonte, A	2
Braghetti, A	1
Bahleda, R	2
Cohen, P	1
Hospitel, M	3
Veyrat-Follet, C	2
Soria, JC	2
Boohaker, RJ	1
Cui, X	1
Stackhouse, M	1
Xu, B	1
Tedeschi, PM	2
Markert, EK	1
Gounder, M	1
Lin, H	1
Dvorzhinski, D	1
Dolfi, SC	1
Chan, LL	1
Qiu, J	1
DiPaola, RS	1
Hirshfield, KM	1
Boros, LG	1
Bertino, JR	2
Oltvai, ZN	1
Vazquez, A	3
Barceló, C	1
Paco, N	1
Morell, M	1
Alvarez-Moya, B	1
Bota-Rabassedas, N	1
Jaumot, M	1
Vilardell, F	1
Capella, G	1
Agell, N	1
Poser, SW	1
Park, DM	1
Androutsellis-Theotokis, A	1
Murakami, H	1
Kurata, T	1
Onozawa, Y	1
Watanabe, J	1
Ono, A	1
Takahashi, T	1
Yamamoto, N	1
Fujisaka, Y	1
Kiyota, H	1
Tanaka, K	1
Nakagawa, K	1
Kuroda, S	1
Cutruzzolá, F	1
Antonov, A	2
Agostini, M	2
Rao, F	1
Cha, J	1
Xu, R	1
Vandiver, MS	1
Tyagi, R	1
Tokhunts, R	1
Koldobskiy, MA	1
Fu, C	1
Barrow, R	1
Fiedler, D	1
Barrow, JC	1
Snyder, SH	1
Eskens, FA	1
Tresca, P	1
Tosi, D	1
Van Doorn, L	1
Fontaine, H	1
Van der Gaast, A	1
Oprea, C	2
Dieras, V	1
Singh, JP	1
Wu, J	1
van den Broek, NJ	1
Mackay, GM	1
Maddocks, OD	3
Del Conte, G	1
Gianni, L	1
Capri, G	1
Varga, A	1
Daglish, B	1
Mamtimin, B	1
Upur, H	1
Kong, B	1
Eli, M	1
Turahun, A	1
Allegra, R	1
Tunesi, S	1
Cilia, R	1
Pezzoli, G	1
Goldwurm, S	1
Low, IC	1
Loh, T	1
Huang, Y	1
Pervaiz, S	1
Fan, J	1
Venneti, S	1
Wan, YW	1
Pawel, BR	1
Finley, LW	1
Lu, C	1
Lindsten, T	1
Qing, G	1
Simon, MC	1
Rabinowitz, JD	1
Xin, M	1
Xie, M	1
Park, D	1
Owonikoko, TK	1
Sica, GL	1
Corsino, PE	1
Zhou, J	1
White, MA	1
Magis, AT	1
Ramalingam, SS	1
Curran, WJ	1
Khuri, FR	1
Deng, X	1
Garufi, A	1
D'Orazi, G	1
Gravel, SP	1
Hulea, L	1
Toban, N	1
Birman, E	1
Blouin, MJ	1
Zakikhani, M	1
St-Pierre, J	1
Pollak, M	1
Morello, M	1
Minieri, M	1
Mehrmohamadi, M	1
Liu, X	1
Shestov, AA	1
Chang, FT	1
Chan, FL	1
R McGhie, JD	1
Udugama, M	1
Mayne, L	1
Collas, P	1
Mann, JR	1
Wong, LH	1
Olazabal-Herrero, A	1
García-Santisteban, I	1
Rodríguez, JA	1
Lin, S	1
Cai, Z	1
Bordeleau, F	1
Califano, JP	1
Negrón Abril, YL	1
Mason, BN	1
LaValley, DJ	1
Shin, SJ	1
Weiss, RS	1
Reinhart-King, CA	1
Yamada, N	1
Tanaka, T	1
Hori, T	1
Yokoyama, S	1
Hayakawa, Y	1
Yano, S	1
Fukuoka, J	1
Koizumi, K	1
Saiki, I	1
Sakurai, H	2
Zhao, M	1
Gjerset, RA	1
Tsun, ZY	1
Possemato, R	1
Li, C	3
Zhou, X	1
Lu, Y	1
Tao, D	1
Hu, W	1
Zheng, X	1
Bian, S	1
Vincent, EE	1
Sergushichev, A	1
Griss, T	1
Gingras, MC	1
Samborska, B	1
Ntimbane, T	1
Coelho, PP	1
Blagih, J	1
Raissi, TC	1
Choinière, L	1
Bridon, G	1
Loginicheva, E	1
Flynn, BR	1
Thomas, EC	1
Tavaré, JM	1
Avizonis, D	1
Pause, A	1
Elder, DJ	1
Artyomov, MN	1
Jones, RG	1
Bakkenist, CJ	1
Beumer, JH	1
Schmitz, JC	1
Grant, NJ	1
Coates, PJ	2
Woods, YL	1
Bray, SE	1
Morrice, NA	1
Hastie, CJ	1
Lamont, DJ	1
Carey, FA	1
Sutherland, C	1
Adams, PD	1
Parker, SJ	1
Mullarky, E	1
Lucki, NC	1
Beheshti Zavareh, R	1
Anglin, JL	1
Gomes, AP	1
Wong, JC	1
Christen, S	1
Takahashi, H	1
Singh, PK	1
Blenis, J	1
Warren, JD	1
Fendt, SM	1
Asara, JM	1
Lyssiotis, CA	1
Lairson, LL	1
Cantley, LC	2
García-Bermúdez, J	1
Cuezva, JM	1
Meiser, J	1
Yang, M	1
Pavlov, VA	1
Kotomtsev, VV	1
Doronin, AI	1
Sabadash, EV	1
Eron, SJ	1
Raghupathi, K	1
Hardy, JA	1
Ravez, S	1
Spillier, Q	1
Marteau, R	1
Feron, O	1
Frédérick, R	1
Nilsson, R	1
Roci, I	1
Watrous, J	1
Jain, M	1
Shreeram, S	1
Hee, WK	1
Bulavin, DV	1
Klotz, K	1
Cepeda, D	1
Tan, Y	1
Sun, D	1
Sangfelt, O	1
Spruck, C	1
Vazquez-Martin, A	1
Oliveras-Ferraros, C	1
Bernadó, L	1
López-Bonet, E	1
Menendez, JA	1
Sgarra, R	1
Maurizio, E	1
Zammitti, S	1
Lo Sardo, A	1
Giancotti, V	1
Manfioletti, G	1
Aslan, JE	1
You, H	1
Williamson, DM	1
Endig, J	1
Youker, RT	1
Thomas, L	1
Shu, H	1
Du, Y	1
Milewski, RL	1
Brush, MH	1
Possemato, A	1
Sprott, K	1
Fu, H	1
Greis, KD	1
Runckel, DN	1
Vogel, A	1
Thomas, G	1
Bergwitz, C	1
Banerjee, S	2
Abu-Zahra, H	1
Kaji, H	1
Miyauchi, A	1
Sugimoto, T	1
Jüppner, H	1
Hussain, A	1
Melville, JL	1
Hirst, JD	1
Bar, JK	1
Słomska, I	1
Rabczyńki, J	1
Noga, L	1
Gryboś, M	1
Vichalkovski, A	1
Gresko, E	1
Hess, D	1
Restuccia, DF	1
Hemmings, BA	2
Peronneau, P	1
Leguerney, I	1
Roche, A	1
Cosgrove, D	1
Rode, JE	1
Dobrowolski, JC	1
Sadlej, J	1
Kreis, NN	1
Sanhaji, M	1
Krämer, A	1
Sommer, K	1
Rödel, F	1
Strebhardt, K	1
Yuan, J	1
Durgan, J	1
Parker, PJ	1
Slee, EA	2
Benassi, B	1
Goldin, R	1
Zhong, S	1
Ratnayaka, I	1
Blandino, G	1
Wang, P	1
Wu, F	1
McMullen, T	1
Young, LC	1
Ingham, RJ	1
Lai, R	1
Kelley, LC	1
Hayes, KE	1
Ammer, AG	1
Martin, KH	1
Weed, SA	1
Cai, YC	1
Zou, Y	1
Xian, LJ	1
Anupriya, G	1
Roopa, K	1
Basappa, S	1
Chong, YS	1
Annamalai, L	1
Lin, RZ	1
Wang, TP	1
Hung, RJ	1
Chuang, YJ	1
Chien, CC	1
Chang, HY	1
Lavoie, G	1
St-Pierre, Y	1
Zhang, XP	1
Liu, F	1
Wang, W	1
Subbiah, IM	1
Lenihan, DJ	1
Tsimberidou, AM	1
Jiang, P	1
Du, W	1
Qiao, M	1
Yang, K	1
Fen, J	1
Fang, H	1
Gong, J	1
Spear, MA	1
Mita, A	1
Mita, M	1
Tsuchimoto, T	1
Sakata, K	1
Someya, M	1
Yamamoto, H	1
Hirayama, R	1
Matsumoto, Y	1
Furusawa, Y	1
Hareyama, M	1
Lin, YS	1
Huang, LD	1
Lin, CH	2
Huang, PH	1
Chen, YJ	1
Wong, FH	1
Lin, CC	1
Fu, SL	2
Ditte, P	1
Dequiedt, F	1
Svastova, E	1
Hulikova, A	1
Ohradanova-Repic, A	1
Zatovicova, M	1
Csaderova, L	1
Kopacek, J	1
Supuran, CT	1
Pastorekova, S	1
Pastorek, J	1
Zhang, WC	1
Shyh-Chang, N	1
Yang, H	1
Rai, A	1
Umashankar, S	1
Ma, S	1
Soh, BS	1
Sun, LL	1
Tai, BC	1
Nga, ME	1
Bhakoo, KK	1
Jayapal, SR	1
Nichane, M	1
Yu, Q	1
Ahmed, DA	1
Tan, C	1
Sing, WP	1
Tam, J	1
Thirugananam, A	1
Noghabi, MS	1
Pang, YH	1
Ang, HS	1
Mitchell, W	1
Robson, P	1
Kaldis, P	1
Soo, RA	1
Swarup, S	1
Lim, EH	1
Lim, B	1
Xie, F	1
Lang, Q	1
Zhou, M	1
Wan, B	1
Huang, Q	1
Yu, L	1
Fingar, DC	1
Inoki, K	1
Varshney, R	1
Sethi, SK	1
Hazari, PP	1
Chuttani, K	1
Soni, S	1
Milton, MD	1
Mishra, AK	1
de Giuseppe, PO	1
Martins, NH	1
Meza, AN	1
dos Santos, CR	1
Pereira, HD	1
Murakami, MT	1
Park, J	2
Piao, L	1
Kong, G	1
Kim, Y	1
Park, KA	1
Hong, J	1
Hur, GM	1
Seok, JH	1
Choi, SW	1
Yoo, BC	1
Brazil, DP	1
Kim, SH	1
Najafov, A	1
Shpiro, N	1
Alessi, DR	1
Hsueh, KW	1
Chang, CB	1
Chang, YL	1
Tan, B	1
Young, DA	1
Lu, ZH	1
Meier, TI	1
Shepard, RL	1
Roth, K	1
Zhai, Y	1
Huss, K	1
Kuo, MS	1
Gillig, J	1
Parthasarathy, S	1
Burkholder, TP	1
Smith, MC	1
Geeganage, S	1
Zhao, G	1
Berkers, CR	1
Mason, SM	1
Zheng, L	1
Gottlieb, E	1
Layton, MJ	1
Saad, M	1
Church, NL	1
Pearson, RB	1
Mitchell, CA	1
Phillips, WA	1
Gatti, L	1
Supino, R	1
Perego, P	1
Pavesi, R	1
Caserini, C	1
Carenini, N	1
Righetti, SC	1
Zuco, V	1
Zunino, F	1
Hammond, EM	1
Dorie, MJ	1
Giaccia, AJ	1
Tinkelenberg, BA	1
Fazzone, W	1
Lynch, FJ	1
Ladner, RD	1
STOCK, CC	3
REILLY, HC	2
BUCKLEY, SM	2
CLARKE, DA	2
RHOADS, CP	2
ELLISON, RR	1
KARNOFSKY, DA	1
STERNBERG, SS	1
MURPHY, ML	1
BURCHENAL, JH	1
KIT, S	3
SANTAMARIA, L	1
FERRARI, F	1
GRAHAM, OL	2
POTTER, M	2
LAW, LW	1
LINDNER, A	1
JACQUEZ, JA	2
PINE, EK	1
HUTCHISON, DJ	1
HENDERSON, JF	1
JUNGA, IG	1
BAKER, BR	1
NYHAN, WL	1
LOH HOEHN-SARIC, E	1
MELONI, GA	1
GENTY, N	1
VENDRELY, R	1
RYAN, WL	1
LORINCZ, AB	1
SCHINDLER, R	1
MORSE, PA	1
POTTER, VR	1
SUGIURA, K	1
LEVI, I	1
BLONDAL, H	1
LOZINSKI, E	1
MORET, V	1
SPERTI, S	1
SILIPRANDI, N	1
Lorimore, SA	1
Lindsay, KJ	1
Wright, EG	1
Yeh, E	1
Cunningham, M	1
Arnold, H	1
Chasse, D	1
Monteith, T	1
Ivaldi, G	1
Hahn, WC	1
Stukenberg, PT	1
Shenolikar, S	1
Uchida, T	1
Counter, CM	1
Nevins, JR	1
Means, AR	1
Sears, R	1
Basu, S	1
Ma, R	1
Mikulla, B	1
Bradley, M	1
Moulton, C	1
Basu, M	1
Inokuchi, J	1
Vadlamudi, RK	1
Bagheri-Yarmand, R	1
Balasenthil, S	1
Nguyen, D	1
Sahin, AA	1
den Hollander, P	1
Kumar, R	1
Miller, F	1
Kentsis, A	1
Osman, R	1
Pan, ZQ	1
Cheng, JD	1
Valianou, M	1
Canutescu, AA	1
Jaffe, EK	1
Lee, HO	1
Lai, JH	1
Bachovchin, WW	1
Weiner, LM	1
Erdjument-Bromage, H	1
Tempst, P	1
Pandolfi, PP	2
Xu, XM	1
Zhou, YQ	1
Wang, MH	1
Shin, S	1
Lee, Y	1
Kim, W	1
Ko, H	1
Choi, H	1
Kim, K	1
Hori, K	1
Basu, A	1
DuBois, G	1
Haldar, S	1
Bivona, TG	1
Quatela, SE	1
Bodemann, BO	1
Ahearn, IM	1
Soskis, MJ	1
Mor, A	1
Miura, J	1
Wiener, HH	1
Wright, L	1
Saba, SG	1
Yim, D	1
Fein, A	1
Pérez de Castro, I	1
Cox, AD	1
Philips, MR	1
Chaurasia, P	1
Aguirre-Ghiso, JA	1
Liang, OD	1
Gardsvoll, H	1
Ploug, M	1
Ossowski, L	1
Chao, C	1
Herr, D	1
Chun, J	1
Nakamura, Y	2
Futamura, M	1
Kamino, H	1
Yoshida, K	1
Arakawa, H	1
Basbous, J	1
Chalbos, D	1
Hipskind, R	1
Jariel-Encontre, I	1
Piechaczyk, M	1
Huang, WC	1
Ju, TK	1
Hung, MC	1
Chen, CC	1
Dohi, T	1
Xia, F	1
Altieri, DC	1
Teruya-Feldstein, J	1
Bonner, P	1
Bernardi, R	1
Franz, DN	1
Witte, D	1
Cordon-Cardo, C	1
Basson, MD	1
Kitajima, S	1
Kudo, Y	1
Ogawa, I	1
Tatsuka, M	1
Kawai, H	1
Pagano, M	1
Takata, T	1
Ouchi, M	1
Ouchi, T	1
Armata, HL	1
Garlick, DS	1
Sluss, HK	1
Verma, M	1
Martin, HJ	1
Haq, W	1
O'Connor, TR	1
Maser, E	1
Balendiran, GK	1
McDonald, PC	1
Oloumi, A	1
Mills, J	1
Dobreva, I	1
Maidan, M	1
Gray, V	1
Wederell, ED	1
Bally, MB	1
Foster, LJ	1
Dedhar, S	1
Lembach, K	2
Charalampous, FC	2
Snell, K	2
Barnard, GF	1
Staniunas, RJ	1
Puder, M	1
Steele, GD	1
Chen, LB	1
Ullrich, SJ	1
Sakaguchi, K	1
Lees-Miller, SP	1
Fiscella, M	1
Mercer, WE	1
Anderson, CW	1
Appella, E	1
Otvos, L	1
Hoffmann, R	1
Xiang, ZQ	1
O, I	1
Deng, H	1
Wysocka, M	1
Pease, AM	1
Rogers, ME	1
Blaszczyk-Thurin, M	1
Ertl, HC	1
Renwick, SB	1
Baumann, U	1
Ishizuka, M	2
Gong, HC	1
Honjo, Y	1
Nangia-Makker, P	1
Hogan, V	1
Mazurak, N	1
Bresalier, RS	1
Raz, A	1
Wu, X	1
Ranganathan, V	1
Weisman, DS	1
Heine, WF	1
Ciccone, DN	1
O'Neill, TB	1
Crick, KE	1
Pierce, KA	1
Lane, WS	1
Rathbun, G	1
Livingston, DM	1
Weaver, DT	1
Lampe, PD	1
TenBroek, EM	1
Burt, JM	1
Kurata, WE	1
Johnson, RG	1
Lau, AF	1
Deppert, W	1
Göhler, T	1
Koga, H	1
Kim, E	1
Van Aken, H	1
Bode, C	1
Darius, H	1
Diehm, C	1
Encke, A	1
Gulba, DC	1
Haas, S	1
Hacke, W	1
Puhl, W	1
Quante, M	1
Riess, H	1
Scharf, R	1
Schellong, S	1
Schrör, T	1
Schulte, KL	1
Tebbe, U	1
Mazurek, S	1
Zwerschke, W	1
Jansen-Dürr, P	1
Eigenbrodt, E	1
Dittmann, KH	1
Mayer, C	1
Rodemann, HP	1
van Noort, M	1
van de Wetering, M	1
Clevers, H	1
Poste, G	1
Aoyagi, T	1
Takeuchi, T	1
Umezawa, H	1
Danø, K	1
Reich, E	1
Tahira, T	1
Nagao, M	1
Aumont, P	1
Enard, C	1
Expert, D	1
Pieddeloup, C	1
Tancrède, C	1
Andremont, A	1
Knox, WE	1
Herzfeld, A	1
Hudson, J	1
Tisman, G	1
Herbert, V	1
Go, LT	1
Brenner, L	1
Hanika, A	1
Krohn, E	1
Müller, G	1
Tabatabai, A	1
Groth, DP	1
D'Angelo, JM	1
Vogler, WR	1
Mingioli, ES	1
Betz, B	1
Björnesjö, KB	1